الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
Background& Aim: HCV was considered as a major health problem in Egypt before the
evolution of direct acting antiviral drugs (DAAs). The benefit of treatment of HCV with DAAs
in patients with decompensated liver cirrhosis (DLC) is still unclear. We evaluated the degree
of improvement in hepatic decompensation events and quality of life in treated and untreated
patients with DLC.
Methods: One hundred and fifty patients with HCV related DLC were included,75 of them
received treatment (group I) in form of sofosbuvir with either daclatasvir or ledipasvir for 24
weeks without ribavirin or for 12 weeks with ribavirin while the other 75 patients didn’t
receive treatment as a comparable group (group II). Patients achieved SVR at 12 weeks were
assessed regarding to decompensation events, MELD score, Child Torcout Pugh (CTP) score,
biochemical changes and quality of life (applied on Mcguill quality of life questionnaire)
before starting treatment and 6 months after treatment and compared them with untreated
patients.
Results: Forty two patients (%56) received sofosbuvir with daclatasvir for 24 weeks without
ribavirin and 19 patients received sofosbuvir with ledipasvir for 24 weeks without ribavirin.
MELD score improved in treated patients (mean change was -1.73) but worsened in untreated
patients (mean change was +11.8) before and after 6 months. Also, CTP score improved
significantly (P<0.001). Serum albumin, prothrombin time, bilirubin, alpha fetoprotein and
ALT improved in treated patients (P <0.001). Health related quality of life improved in treated
patients (mean change was +17.65) and worsened in untreated ones (mean change was - 18.68)
[P <0.001]. There were no significant predictors for starting treatment in our study.
Conclusion: Treated patients with DLC showed improvement in their liver functions and
health related quality of life. Those patients need longer durations of follow up for
decompensation events.